Table 1.
Clinical Characteristics of All Study Subjects Including Healthy Controls (HC) and Diabetes Subjects (DM).
| Characteristic | Healthy controls (HC) | Diabetes group (DM) | p for DM vs HC | p for LDIFLARE vs POCD in HC (DM) |
|---|---|---|---|---|
| N | 80 | 162 | — | — |
| Age (years) | 39.67 ± 15.17 | 47.96 ± 13.98 | 0.22 | — |
| Female/male sex | 38/42 | 70/92 | 0.57 | — |
| Duration of diabetes (years) | - | 11.4 ± 9.4 | — | — |
| BMI (kg/m2) | 26.07 ± 4.37 | 29.26 ± 3.45 | 0.004 | — |
| Systolic blood pressure (mm Hg) | 118 ± 19 | 133 ± 15 | <0.0001 | — |
| Diastolic blood pressure (mm Hg) | 67 ± 6 | 83 ± 11 | <0.0001 | — |
| Vibration perception threshold (mV) | 6.08 ± 2.09 | 19.4 + 11.1 | <0.0001 | — |
| LDIflare (cm2) | 9.11 ± 2.17 | 5.81 ± 2.09 | <0.0001 | — |
| POCD outcomes | ||||
| Sural nerve conduction velocity (SNCV, m/s) | 50.22 ± 5.69 | 42.04 ± 9.11 | <0.0001 | <0.0001 (0.002) |
| Sural nerve amplitude potential (SNAP, µV) | 18.49 ± 4.13 | 10.13 ± 3.12 | <0.0001 | <0.0001 (0.003) |
BMI, body mass index; LDIflare, laser Doppler imager flare; N, number of patients; POCD, point-of-care device; SNAP, sural nerve amplitude potential; SNCV, sural nerve conduction velocity. Significance = p < .05.